Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations
暂无分享,去创建一个
[1] N. Kamar,et al. Treatment of hepatitis E virus , 2016, Current opinion in infectious diseases.
[2] X. de Lamballerie,et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. , 2016, Journal of hepatology.
[3] M. B. Pisano,et al. Corrigendum to "Hepatitis E virus infection in the HIV-positive patient" [J. Clin. Virol. 80 (2016) 102-106]. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[4] T. Kuntzer,et al. Hepatitis E virus infection as a direct cause of neuralgic amyotrophy , 2016, Muscle & nerve.
[5] J. Izopet,et al. Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis , 2016, Viruses.
[6] M. B. Pisano,et al. Hepatitis E virus infection in the HIV-positive patient. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[7] J. Neyts,et al. Update on hepatitis E virology: Implications for clinical practice. , 2016, Journal of hepatology.
[8] J. Neyts,et al. Extra‐hepatic replication and infection of hepatitis E virus in neuronal‐derived cells , 2016, Journal of viral hepatitis.
[9] Guangdi Li,et al. Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.
[10] R. Shi,et al. Evidence of Hepatitis E virus breaking through the blood–brain barrier and replicating in the central nervous system , 2016, Journal of viral hepatitis.
[11] M. Manns,et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome , 2016, Gut.
[12] H. Blum. History and Global Burden of Viral Hepatitis , 2016, Digestive Diseases.
[13] M. Peppelenbosch,et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection , 2016, Journal of viral hepatitis.
[14] P. Cintas,et al. Hepatitis E virus and neurological injury , 2016, Nature Reviews Neurology.
[15] T. Pietschmann,et al. Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication , 2016, Antimicrobial Agents and Chemotherapy.
[16] J. Izopet,et al. Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy , 2015, Antimicrobial Agents and Chemotherapy.
[17] E. Domingo,et al. Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold. , 2015, Current topics in microbiology and immunology.
[18] J. C. Nuño,et al. Theories of Lethal Mutagenesis: From Error Catastrophe to Lethal Defection. , 2015, Current topics in microbiology and immunology.
[19] P. Schuster,et al. What Is a Quasispecies? Historical Origins and Current Scope. , 2015, Current topics in microbiology and immunology.
[20] P. Couzigou,et al. Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E , 2015, Emerging infectious diseases.
[21] J. Prpić,et al. The application of single strand conformation polymorphism (SSCP) analysis in determining Hepatitis E virus intra-host diversity. , 2015, Journal of virological methods.
[22] F. Negro,et al. Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes , 2015, Gut.
[23] O. Ramilo,et al. New options in the treatment of respiratory syncytial virus disease. , 2015, The Journal of infection.
[24] M. Manns,et al. The impact of hepatitis E in the liver transplant setting. , 2014, Journal of hepatology.
[25] M. Manns,et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. , 2014, Gastroenterology.
[26] M. Manns,et al. Hepatitis E in Germany--an under-reported infectious disease. , 2014, Deutsches Arzteblatt international.
[27] P. Simmonds,et al. Consensus proposals for classification of the family Hepeviridae , 2014, The Journal of general virology.
[28] H. Dalton,et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection , 2014, Neurology.
[29] R. Viswanathan. Infectious hepatitis in Delhi (1955-56): a critical study-epidemiology. 1957. , 2013, The National medical journal of India.
[30] S. Emerson,et al. Ribavirin Inhibits In Vitro Hepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon , 2013, Antimicrobial Agents and Chemotherapy.
[31] J. Neyts,et al. Intervention strategies for emerging viruses: use of antivirals , 2013, Current Opinion in Virology.
[32] A. Perelson,et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C , 2013, Gut.
[33] Kenneth A. Johnson,et al. NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase , 2013, Proceedings of the National Academy of Sciences.
[34] T. Liang,et al. The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C , 2012, Antiviral chemistry & chemotherapy.
[35] M. Denison,et al. Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses , 2012, Current Opinion in Virology.
[36] L. Rostaing,et al. Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients , 2012, Journal of Virology.
[37] E. Domingo,et al. Viral Quasispecies Evolution , 2012, Microbiology and Molecular Reviews.
[38] M. Manns,et al. Pathogenesis and treatment of hepatitis e virus infection. , 2012, Gastroenterology.
[39] Y. Hiasa,et al. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. , 2012, The Journal of infectious diseases.
[40] Suresh Mahalingam,et al. Chikungunya: a re-emerging virus , 2012, The Lancet.
[41] J. Neyts,et al. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. , 2011, Current opinion in virology.
[42] D. Feigelstock,et al. Selection of hepatitis C virus resistant to ribavirin , 2011, Virology Journal.
[43] S. Günther,et al. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. , 2011, Antiviral research.
[44] S. Panda,et al. Hepatitis E virus replication involves alternating negative- and positive-sense RNA synthesis. , 2011, The Journal of general virology.
[45] E. Domingo,et al. A Multi-Step Process of Viral Adaptation to a Mutagenic Nucleoside Analogue by Modulation of Transition Types Leads to Extinction-Escape , 2010, PLoS pathogens.
[46] Edward C Holmes,et al. The RNA virus quasispecies: fact or fiction? , 2010, Journal of molecular biology.
[47] J. Hoofnagle,et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. , 2010, Gastroenterology.
[48] R. Porte,et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha‐2b , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[49] L. Rostaing,et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] M. Manns,et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[51] E. Domingo,et al. Potential Benefits of Sequential Inhibitor-Mutagen Treatments of RNA Virus Infections , 2009, PLoS pathogens.
[52] M. Lai,et al. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities , 2009, FEBS letters.
[53] M. Eigen,et al. The Hypercycle: A principle of natural self-organization , 2009 .
[54] E. Domingo,et al. Counteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic Treatment , 2009, PloS one.
[55] G. Moonen,et al. Guillain-Barré syndrome following hepatitis E. , 2009, World journal of gastroenterology.
[56] C. Roth,et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. , 2008, Antiviral research.
[57] J. Hoofnagle,et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop , 2007, Hepatology.
[58] M. Cam,et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response , 2007, Hepatology.
[59] J. Deval,et al. Pyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B Polymerase , 2007, Antimicrobial Agents and Chemotherapy.
[60] R. Sidwell,et al. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. , 2007, Antiviral research.
[61] E. Domingo,et al. Foot-and-Mouth Disease Virus Mutant with Decreased Sensitivity to Ribavirin: Implications for Error Catastrophe , 2006, Journal of Virology.
[62] C. Jonsson,et al. Activity of Ribavirin against Hantaan Virus Correlates with Production of Ribavirin-5′-Triphosphate, Not with Inhibition of IMP Dehydrogenase , 2006, Antimicrobial Agents and Chemotherapy.
[63] K. Gutkowski,et al. [Viral hepatitis during pregnancy]. , 2006, Ginekologia polska.
[64] Alexander E Gorbalenya,et al. Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Vignuzzi,et al. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population , 2006, Nature.
[66] C. Cameron,et al. Mechanisms of action of ribavirin against distinct viruses , 2005, Reviews in medical virology.
[67] L. Beeren,et al. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. , 2005, RNA.
[68] J. Pelletier,et al. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. , 2005, RNA.
[69] N. Pariente,et al. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. , 2005, Virus research.
[70] E. De Clercq,et al. The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase , 2005, Journal of Virology.
[71] Marco Vignuzzi,et al. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. , 2005, Virus research.
[72] M. Siriwardana,et al. Evidence for hepatitis E virus quasispecies. , 2004, The Journal of general virology.
[73] Jean-Louis Romette,et al. A Structural Basis for the Inhibition of the NS5 Dengue Virus mRNA 2′-O-Methyltransferase Domain by Ribavirin 5′-Triphosphate* , 2004, Journal of Biological Chemistry.
[74] A. Amoroso,et al. The role of ribavirin in the combination therapy of hepatitis C virus infection. , 2004, Current pharmaceutical design.
[75] Isabelle Bougie,et al. The Broad Spectrum Antiviral Nucleoside Ribavirin as a Substrate for a Viral RNA Capping Enzyme* , 2004, Journal of Biological Chemistry.
[76] A. Neumann,et al. Antiviral action of ribavirin in chronic hepatitis C. , 2004, Gastroenterology.
[77] S. Briolant,et al. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. , 2004, Antiviral research.
[78] E. Domingo,et al. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. , 2003, Virology.
[79] J. Pawlotsky,et al. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. , 2003, Antiviral research.
[80] Julie K. Pfeiffer,et al. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[81] R. Garofalo,et al. Ribavirin Treatment Up-Regulates Antiviral Gene Expression via the Interferon-Stimulated Response Element in Respiratory Syncytial Virus-Infected Epithelial Cells , 2003, Journal of Virology.
[82] Natale Scaramozzino,et al. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. , 2003, Antiviral research.
[83] William E. Severson,et al. Ribavirin Causes Error Catastrophe during Hantaan Virus Replication , 2003, Journal of Virology.
[84] E. Schmidt,et al. Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System , 2002, Journal of Virology.
[85] Z. Hong,et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection , 2002, Hepatology.
[86] R. Lanford,et al. Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes , 2001, Journal of Virology.
[87] N. Snell. Ribavirin - current status of a broad spectrum antiviral agent , 2001, Expert opinion on pharmacotherapy.
[88] S. Goodman,et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.
[89] J. Arnold,et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.
[90] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[91] O. Weiland,et al. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. , 1998, The Journal of general virology.
[92] V. Khoshoo,et al. Reduced long‐term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report , 1998, Pediatric pulmonology.
[93] G. Lemay,et al. Viral and cellular enzymes involved in synthesis of mRNA cap structure. , 1997, Virology.
[94] P. D. Nagy,et al. A novel 3'-end repair mechanism in an RNA virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[95] M A Nowak,et al. Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[96] T. Mosmann,et al. The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.
[97] E. De Clercq,et al. Molecular approaches for the treatment of hemorrhagic fever virus infections. , 1993, Antiviral research.
[98] A. W. Tam,et al. Hepatitis E virus (HEV): The novel agent responsible for enterically transmitted non-A, non-B hepatitis , 1991, Gastroenterologia Japonica.
[99] J. Huggins. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.
[100] K. O'connell,et al. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription , 1988, Antimicrobial Agents and Chemotherapy.
[101] F. Hayden,et al. Oral ribavirin treatment of influenza A and B , 1987, Antimicrobial Agents and Chemotherapy.
[102] V. Stollar,et al. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. , 1987, Virology.
[103] V. Knight,et al. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. , 1985, Antiviral research.
[104] E. Domingo,et al. Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. , 1983, Virology.
[105] J. Holland,et al. High multiplicities of infection favor rapid and random evolution of vesicular stomatitis virus. , 1982, Virology.
[106] Katherine Spindler,et al. Rapid evolution of RNA genomes. , 1982, Science.
[107] R. Couch,et al. RIBAVIRIN SMALL-PARTICLE AEROSOL TREATMENT OF INFLUENZA , 1981, The Lancet.
[108] D. Alling,et al. Lack of Interference of Guanosine with Ribavirin Aerosol Treatment of Influenza A Infection in Mice , 1981, Antimicrobial Agents and Chemotherapy.
[109] S. Skidmore,et al. Incidence and severity of viral hepatitis in pregnancy. , 1981, The American journal of medicine.
[110] E. Domingo,et al. Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. , 1980, Gene.
[111] R. Smith,et al. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. , 1979, Biochemical and biophysical research communications.
[112] T. Zimmerman,et al. Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. , 1978, Biochemical pharmacology.
[113] M. Eigen,et al. The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. , 1977, Die Naturwissenschaften.
[114] L. Philipson,et al. Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate , 1977, Antimicrobial Agents and Chemotherapy.
[115] W. Müller,et al. Virazole (1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide; A cytostatic agent , 1977 .
[116] R. J. Bauer,et al. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[117] R. K. Robins,et al. Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.
[118] L. Sexton. The Treatment of Yellow Fever , 1903, The Indian medical gazette.
[119] G. Marano,et al. Hepatitis E: an old infection with new implications. , 2015, Blood transfusion = Trasfusione del sangue.
[120] V. Mishra,et al. Viral Hepatitis in Pregnancy--A study of its Effect on Maternal and Foetal Outcome. , 2015, The Journal of the Association of Physicians of India.
[121] A. Randolph,et al. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. , 2004, The Cochrane database of systematic reviews.
[122] A S Perelson,et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.
[123] E. Domingo,et al. RNA virus mutations and fitness for survival. , 1997, Annual review of microbiology.
[124] J. B. Antczak,et al. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. , 1989, Virology.
[125] J. McCormick,et al. Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.
[126] W. Müller,et al. Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent. , 1977, Biochemical pharmacology.